Photo: The Economic Times Markets
Business & Finance
Sun Pharma’s specialty portfolio, Organon deal to drive growth
TL;DR
- Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. 6% from last year.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 1, 2026 · Updated 11/2/2026, 1:30:15 AM · Reported with: The Economic Times Markets
Sources (1)
NRI Bytes writes its own articles from the reporting below.
The Economic Times Markets — Sun Pharma’s specialty portfolio, Organon deal to drive growthUp next · Business & Finance
Bengaluru techie couple spends 3 times an IT fresher's salary on travel every month: How much do they spend?
Read next →
More stories
Business & Finance
Top LIC Schemes For Children: Securing Higher Education, Financial Milestones
44m ago
Business & Finance
ITC Q2 Results: Profit Plunges 20% As Margin Shrinks, Revenue Up Slightly
44m ago
Business & Finance
What Is China's Secret Space Plane Doing Above Earth? US Releases Rare Photograph
44m ago
Business & Finance
Koffee With Karan 9: Saif Ali Khan Checks Kareena Kapoor As She Calls Herself Bollywood's No. 1 Actress
44m ago
